An antineoplastic composition for use in treating cancer in a human subject comprising: a) a cellular energy inhibitor having a structure according to formula I ** Formula ** in which X is selected from the group that It consists of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide and amine oxide； and R is selected from the group consisting of: OR ', N (R ") 2, C (O) R"', C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H and an alkali metal； where R 'represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C (O) R "', R" represents H, C1-C6 alkyl or C6-C12 aryl and R '"represents H, C1 alkyl -C20 or C6-C12 aryl, b) at least one alditol, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing, preferably in a concentration from about 0.1 mM to about 250 mM, more preferably from about 0.5mM to about 25mM； c) a glycolysis inhibitor including 2-deoxyglucose； and d) a biological buffer including a citrate buffer that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize the metabolic by-products of the cellular energy inhibitor.Una composición antineoplásica para su uso en el tratamiento del cáncer en un sujeto humano que comprende: a) un inhibidor de la energía celular que tiene una estructura de acuerdo con la fórmula I**Fórmula** en la que X está seleccionado del grupo que consiste en: un nitro, un imidazol, un haluro, sulfonato, un carboxilato, un alcóxido y óxido de amina； y R está seleccionado del grupo que consiste en: OR', N(R")2, C(O)R"', alquilo C1-C6, arilo C6-C12, heteroalquilo C1-C6, un heteroarilo C6-C12, H y un metal alcalino； donde R' representa H, metal alcalino, alquilo C1-C6, arilo C6-C12 o C(O)R"', R" representa H, alquilo C1-C6 o arilo C6-C12 y R'" representa H, alquilo C1-C20 o arilo C6-C12, b) al menos un alditol, que estabiliza el inhibidor de la energía celular previniendo sustancialmente que el inhib
